---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-015576"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T18:54:51.324637+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health raises ~$5.5M in offering; preliminary cash $2.6M as of Dec 31, 2023

## Summary
- Gross proceeds of ~$5.5M from sale of 1,371,000 shares at $3.50/share plus warrants.
- CEO Nicole Sandford participated in offering; also sold 2,400 shares at $4.255/share.
- Preliminary cash and equivalents of $2.6M as of Dec 31, 2023, excluding $0.3M restricted cash.
- Existing warrants with exercise price of $13.20 amended to $4.00, expiration extended to Jan 2029.
- Offering is expected to close Jan 26, 2024.

## SEC filing metadata
- accession: 0001193125-24-015576
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000119312524015576/0001193125-24-015576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000119312524015576/d699303d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-015576
- JSON: https://secwatch.observer/filing/0001193125-24-015576.json
- Plain text: https://secwatch.observer/filing/0001193125-24-015576.txt

## Key facts
- Material Agreements
  Aspira Women's Health Inc. entered into Securities Purchase Agreement with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company valued at gross proceeds to the Company from the Offering are expected to be approximately $5.5 million (effective 2024-01-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company
  - Value: gross proceeds to the Company from the Offering are expected to be approximately $5.5 million
  - Effective: 2024-01-24
  source text: ) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524015576/0001193125-24-015576-index.htm
- Material Agreements
  Aspira Women's Health Inc. amended certain existing warrants (effective 2024-01-26).
  - Action: amendment
  - Effective: 2024-01-26
  source text: The Company has also agreed that certain existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $13.20 per share and a termination date of August 25, 2027, will be amended, effective upon the closing of the Offering, so that the amended warrants will have a reduced exercise price of $4.00 per share and a new termination date of January 26, 2029.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524015576/0001193125-24-015576-index.htm
- Material Agreements
  Aspira Women's Health Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds generated from the Offering (effective 2024-01-24).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: 7.0% of the aggregate gross proceeds generated from the Offering
  - Effective: 2024-01-24
  source text: On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524015576/0001193125-24-015576-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.